[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections].
OBJECTIVE
The objective of this open-label, single-arm, multicenter study was to assess the efficacy and safety of levofloxacin in the treatment of complicated urinary tract infections.


METHODS
A total of 72 outpatients with symptoms/signs of urinary tract infection and underlying anatomic or functional abnormality of the urinary tract was enrolled to receive levofloxacin 250 mg orally once daily for 10 days. Return visits were scheduled at 3-5 days (early follow-up visit) and 4-6 weeks after completion of therapy (long-term follow-up). At each visit symptoms and signs were assessed, possible adverse events were recorded and a urine specimen was obtained for culture.


RESULTS
At 3-5 days post-therapy clinical success rate was 94% and the overall microbiological eradication rate of pathogens was 94%. Microbiological eradication rate with respect to patients was 86%. Treatment failed in 4 patients and 2 patients had superinfections with pathogens still susceptible to levofloxacin. At long-term follow-up visit 3 reinfections were observed in patients previously cured at early follow-up. Drug-related adverse events were reported by 2 patients.


CONCLUSIONS
These study results indicate that levofloxacin 250 mg orally once daily for 10 days is an effective and well tolerated treatment of complicated urinary tract infections.
Clinica Urologica, IRCCS Ospedale Maggiore di Milano.
Alberto
A
Trinchieri
Federico
F
Marchetti
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy; D012008:Recurrence; D012449:Safety; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D015163:Superinfection; D016896:Treatment Outcome; D014551:Urinary Tract / Q000002:abnormalities; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin